10.97
Fibrogen Inc stock is traded at $10.97, with a volume of 16,206.
It is up +3.98% in the last 24 hours and down -8.81% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
See More
Previous Close:
$10.55
Open:
$10.78
24h Volume:
16,206
Relative Volume:
0.38
Market Cap:
$44.36M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
-3.744
EPS:
-2.93
Net Cash Flow:
$-317.54M
1W Performance:
-3.01%
1M Performance:
-8.81%
6M Performance:
+58.30%
1Y Performance:
+22.81%
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
FGEN
Fibrogen Inc
|
10.97 | 42.66M | 147.75M | -284.23M | -317.54M | -2.93 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
Jun-26-23 | Downgrade | Stifel | Buy → Hold |
Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
Jun-02-23 | Upgrade | Stifel | Hold → Buy |
Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
Jul-16-21 | Downgrade | Stifel | Buy → Hold |
Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
Feb-01-21 | Initiated | H.C. Wainwright | Buy |
Oct-26-20 | Initiated | Raymond James | Underperform |
Jul-10-20 | Resumed | Stifel | Buy |
May-01-20 | Initiated | Cowen | Market Perform |
Apr-27-20 | Initiated | BofA/Merrill | Neutral |
May-29-19 | Resumed | Goldman | Neutral |
May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
Apr-12-19 | Initiated | Piper Jaffray | Neutral |
Feb-11-19 | Resumed | Stifel | Buy |
Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
Aug-08-17 | Reiterated | Leerink Partners | Outperform |
Aug-08-17 | Reiterated | Stifel | Buy |
Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
Jul-11-17 | Initiated | Jefferies | Buy |
Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
Jan-21-16 | Initiated | Credit Suisse | Neutral |
Dec-04-15 | Initiated | Citigroup | Buy |
Sep-23-15 | Initiated | Lake Street | Hold |
Jul-29-15 | Initiated | Citigroup | Buy |
Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
How FibroGen Inc. (1FG0) stock reacts to monetary easingWatch List & Technical Buy Zone Confirmation - newser.com
Forecasting FibroGen Inc. price range with options dataJuly 2025 Snapshot & AI Powered Trade Plan Recommendations - newser.com
How to read the order book for FibroGen Inc.Earnings Overview Report & Advanced Swing Trade Entry Plans - newser.com
Real time breakdown of FibroGen Inc. stock performance2025 Short Interest & Growth Oriented Trading Recommendations - newser.com
Risk vs reward if holding onto FibroGen Inc.Market Rally & AI Driven Price Predictions - newser.com
Sentiment analysis tools applied to FibroGen Inc.July 2025 Technicals & High Conviction Buy Zone Alerts - newser.com
Applying Wyckoff theory to FibroGen Inc. stockInflation Watch & Consistent Return Investment Signals - newser.com
Can you recover from losses in FibroGen Inc.Market Growth Summary & Real-Time Volume Analysis - newser.com
Relative strength of FibroGen Inc. in sector analysis2025 Historical Comparison & Verified Short-Term Plans - newser.com
Custom watchlist performance reports with FibroGen Inc.2025 Macro Impact & Verified Momentum Watchlists - newser.com
Real time social sentiment graph for FibroGen Inc.Earnings Beat & Intraday High Probability Alerts - newser.com
Is now a turning point for FibroGen Inc.2025 Price Action Summary & AI Driven Price Forecasts - newser.com
Real time scanner hits for FibroGen Inc. explainedTrade Risk Assessment & Daily Volume Surge Trade Alerts - newser.com
Will FibroGen Inc. (1FG0) stock see valuation expansion2025 Technical Patterns & Risk Adjusted Swing Trade Ideas - newser.com
Long term hold vs stop loss in FibroGen Inc.2025 Trading Volume Trends & Entry Point Confirmation Signals - newser.com
Live market analysis of FibroGen Inc.Buy Signal & Expert Approved Momentum Trade Ideas - newser.com
Reversal indicators forming on FibroGen Inc. stockInflation Watch & Fast Exit and Entry Strategy Plans - newser.com
Published on: 2025-10-03 05:46:29 - newser.com
What analysts say about FibroGen Inc stockMid Cap Growth Trends & Maximize ROI With Proven Growth Stocks - earlytimes.in
FibroGen Inc Stock Analysis and ForecastEquity Performance Review & High Return Portfolio Growth - earlytimes.in
What drives FibroGen Inc stock priceMonthly Performance Summary & Reap the Rewards of Patience + Planning - earlytimes.in
What analysts say about FibroGen Inc 1FG0 stockBollinger Bands Signals & Exceptional Capital Growth - earlytimes.in
FibroGen stock advances as H.C. Wainwright reiterates Buy rating on FG-3246 progress - Investing.com Nigeria
FibroGen stock advances as H.C. Wainwright reiterates Buy rating on FG-3246 progress By Investing.com - Investing.com South Africa
William Blair Remains a Hold on FibroGen (FGEN) - The Globe and Mail
H.C. Wainwright Maintains FibroGen(FGEN.US) With Buy Rating, Maintains Target Price $43 - 富途牛牛
FibroGen initiates phase 2 trial of FG-3246 for prostate cancer By Investing.com - Investing.com South Africa
FibroGen initiates phase 2 trial of FG-3246 for prostate cancer - Investing.com India
FGEN: HC Wainwright & Co. Reiterates 'Buy' Rating with $43 Targe - GuruFocus
FibroGen (FGEN) Launches Phase 2 Trial for Antibody-Drug Conjuga - GuruFocus
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fibrogen Inc Stock (FGEN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Wettig Thane | CEO |
Mar 24 '25 |
Buy |
0.35 |
145,000 |
50,663 |
543,329 |
Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):